TABLE 6.
Comparative characteristics of the studied groups in terms of CADSS scores measured 30 min after the ketamine infusions.
| TRD-MDD-P (n = 17) |
TRD-BD-P (n = 18) |
P-value | |
| I infusion | 0.08921 | ||
| SD | 1.2 (3.3) | 0.4 (1.6) | |
| Range | 0.0–14.0 | 0.0–7.0 | |
| Median (IQR) | 0.0 (1.0) | 0.0 (0.0) | |
| 95% CI | [−0.5; 2.9] | [−0.4; 1.2] | |
| II infusion | 0.54151 | ||
| SD | 15.5 (15.0) | 10.7 (8.5) | |
| Range | 0.0–49.0 | 0.0–33.0 | |
| Median (IQR) | 11.0 (18.0) | 10.5 (12.0) | |
| 95% CI | [7.8; 23.2] | [6.4; 14.9] | |
| III infusion | 0.16071 | ||
| SD | 15.0 (18.7) | 6.9 (6.5) | |
| Range | 0.0–65.0 | 0.0–22.0 | |
| Median (IQR) | 10.0 (10.0) | 3.5 (9.0) | |
| 95% CI | [5.4; 24.6] | [3.6; 10.1] | |
| IV infusion | 0.69211 | ||
| SD | 13.3 (16.9) | 7.7 (6.7) | |
| Range | 0.0–62.0 | 0.0–24.0 | |
| Median (IQR) | 8.0 (17.0) | 7.0 (10.0) | |
| 95% CI | [4.6; 22.0] | [4.3; 11.0] | |
| V infusion | 0.46781 | ||
| SD | 11.3 (9.2) | 7.7 (5.5) | |
| Range | 0.0–28.0 | 0.0–15.0 | |
| Median (IQR) | 9.0 (13.0) | 9.5 (10.0) | |
| 95% CI | [6.6; 16.0] | [4.9; 10.4] | |
| VI infusion | 0.69211 | ||
| SD | 10.2 (11.4) | 6.9 (6.0) | |
| Range | 0.0–35.0 | 0.0–17.0 | |
| Median (IQR) | 7.0 (16.0) | 6.0 (11.0) | |
| 95% CI | [4.4; 16.1] | [3.9; 9.9] | |
| VII infusion | 1.00001 | ||
| SD | 5.4 (10.2) | 2.0 (3.4) | |
| Range | 0.0–33.0 | 0.0–15.0 | |
| Median (IQR) | 1.0 (2.0) | 2.0 (2.0) | |
| 95% CI | [0.2; 10.6] | [0.3; 3.7] | |
| Follow-up | 0.08921 | ||
| SD | 0.2 (0.6) | 0.0 (0.0) | |
| Range | 0.0–2.0 | 0.0–0.0 | |
| Median (IQR) | 0.0 (0.0) | 0.0 (0.0) | |
| 95% CI | [−0.1; 0.5] | [0.0; 0.0] |
1U Mann-Whitney; SD, standard deviation; IQR, interquartile range; TRD-MDD-P, treatment resistant major psychotic depression; TRD-BD-P, treatment resistant bipolar psychotic depression; CADSS, Clinican Administered Dissociative States Scale.